Spyre Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    52990017AIJPRH3HQH40
    ISIN
    US00773J2024 (SYRE)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    1 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    0 / 7

    Profile

    Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Read full profile

    Fundamentals

    Net revenue
    -€755.71K
    Gross margin
    100.0%
    EBIT
    -€139.09M
    EBIT margin
    18,405.3%
    Net income
    -€70.73M
    Net margin
    9,359.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €76.77K -110.2% -€198.40M +180.5%
    €119.41K +55.6% -€234.29M +18.1%
    N/A -€272.67M +16.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Burrows Scott L Chief Financial Officer -18K $16.26 -$299.64K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    George Soros 125K $2.02M -125K Sell

    Earnings Calls

    Latest earnings call: March 7, 2019 (Q4 2018)

    Add to watchlist

    Notifications